Eli Lilly's Oral GLP-1 Therapy Sustains Weight Loss Post-Injection
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.